Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trinity Biotech (TRIBY) -- Ignore unavailable to you. Want to Upgrade?

To: milton who wrote (7367)	11/12/1997 10:35:00 AM
From: Dan Lisman	Read Replies (2) \| Respond to of 14328

Trinity Biotech Signs Contract Extension With Warner Lambert BusinessWire, Wednesday, November 12, 1997 at 10:25 DUBLIN, Ireland--(BW HealthWire)--Nov. 12, 1997--TRINITY BIOTECH plc (NASDAQ:TRIBY), and its partner Applied Biotech Inc., today announced that they have extended their contractual agreement with Warner-Lambert Company for the exclusive supply of pregnancy tests for the over-the-counter (OTC) market in the U.S. The existing contract commenced in September 1993 and was due to expire in August 1998. The extension will allow Trinity Biotech and Applied Biotech Inc. to continue to supply pregnancy test kits to Warner-Lambert until August 2001. The product, which is sold by Warner-Lambert under the brand name ept(R) is the leading OTC pregnancy test in the U.S. having a market share of 23% by volume. ept was relaunched in quarter 4, 1996 in a new product design and presentation. Commenting on the announcement, Brendan Farrell, President of Trinity Biotech and head of Trinity Biotech's U.S. operations stated, "We are very pleased to extend our highly successful relationship with Warner-Lambert. The ept pregnancy test enjoys a leadership position in the U.S. OTC market as a result of its easy to use and rapid one-step technology, coupled with Warner-Lambert's strong branding and merchandising skills." Trinity Biotech develops, manufactures and markets over 90 diagnostic tests which address all three segments of the diagnostic market 1) test kits for the clinical laboratory or traditional market; 2) rapid tests for the emerging point-of-care (POC) market and 3) simplified tests for the over-the-counter (OTC) market. The company's tests are sold around the world in 65 countries. "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995. The statements which are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration (FDA) and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the Company's Securities and Exchange Commission filings. CONTACT: Jonathan O'Connell Chief Financial Officer (800) 603-8076 or INVESTOR RELATIONS CONTACT: Bruce Voss/Olga Fleming olga@lhai.com Lippert/Heilshorn & Associates, Inc. (212) 838-3777 KEYWORD: NEW YORK INDUSTRY KEYWORD: MEDICINE BIOTECHNOLOGY PHARMACEUTICAL PRODUCT Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: businesswire.com Copyright 1997, Business Wire Companies or Securities discussed in this article: Symbol Name NASDAQ:TRIBY Trinity Biotech Plc Spons ADR --------------------------------------------------------------------------------